Annovis Bio, Inc.
Annovis Bio, Inc.
Your view on ANVS
Overview
What the company does, where it operates, and who runs it.
About Annovis Bio, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Maria L. Maccecchini
- Headquarters
- 1055 Westlakes Drive, Malvern, PA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Maria L. Maccecchini
- Headquarters
- 1055 Westlakes Drive, Malvern, PA, US
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.
The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders.
It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Annovis Bio, Inc., and the rating behind it. ANVS last traded at $1.12; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Annovis Bio, Inc.. Starting points for Annovis Bio, Inc.: EPS -$1.32, beta 1.24 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Annovis Bio, Inc.. Annovis Bio, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Annovis Bio, Inc.. Trailing twelve-month EPS for Annovis Bio, Inc. stands at -$1.32. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Annovis Bio, Inc.. Annovis Bio, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Annovis Bio, Inc. valued side by side against its closest peers. Annovis Bio, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Annovis Bio, Inc., and how their positions are changing. At a $47.6M market value, institutional positions materially move Annovis Bio, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Annovis Bio, Inc. executives and directors. Shares of Annovis Bio, Inc. have traded between $1.11 and $7.52 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Annovis Bio, Inc.. Annovis Bio, Inc. is a $47.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Annovis Bio, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Annovis Bio, Inc.. Coverage tracks Annovis Bio, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.